Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily
Article first published online: 6 AUG 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Munksgaard
Volume 63, Issue 9, pages 1228–1234, September 2008
How to Cite
Rozsasi, A., Polzehl, D., Deutschle, T., Smith, E., Wiesmiller, K., Riechelmann, H. and Keck, T. (2008), Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy, 63: 1228–1234. doi: 10.1111/j.1398-9995.2008.01658.x
- Issue published online: 6 AUG 2008
- Article first published online: 6 AUG 2008
- Accepted for publication 21 December 2007
- aspirin desensitization treatment;
- nonsteroidal anti-inflammatory drugs
Background: The daily dose of aspirin in desensitization in aspirin-sensitive asthmatics with nasal polyps is still a matter of debate.
Aims of the study: To compare two doses of aspirin during the first year of desensitization and to evaluate long-term effects on nasal/pulmonary symptoms.
Methods: Patients with positive aspirin provocation test were treated with either 100 or 300 mg aspirin daily.
Results: In all patients taking 100 mg aspirin (n = 7) recurrent nasal polyps were observed. No patient experienced reduction of asthma medication or improvement of pulmonary function. In the 300 mg group no recurrent nasal polyps were seen. Asthma medication could be reduced in three patients, pulmonary function was improved in five patients. Thirty-nine consecutively desensitized patients, taking 300 mg aspirin, showed significant improvement of olfaction and polyp-free nasal passages during the first year of therapy. After a median follow-up of 27 months no sinus revision surgery was necessary.
Conclusions: Aspirin desensitization followed by 300 mg aspirin daily is efficacious and results in polyp-free nasal airways, improvement of sense of smell, and reduction of the need for sinus revision surgery for recurrent nasal polyps. Aspirin in a dose of 100 mg daily is not sufficient to effectively reduce nasal and bronchial or pulmonary symptoms and to prevent recurrent nasal polyps by at least the first 12 months of treatment.